SK Biopharmaceuticals

326030.KO

82.50 USD

0.38

+0.46%

Overview

Last close

82.50 usd

Market cap

6.46B usd

52 week high

95.49 usd

52 week low

62.52 usd

Target price

102.03 usd

Valuation

P/E

N/A

Forward P/E

81.3008

Price/Sales

13.6473

Price/Book Value

12.7108

Enterprise Value

5.85B usd

EV/Revenue

12.3556

EV/EBITDA

47.6488

Key financials

Revenue TTM

473.39M usd

Gross Profit TTM

449.68M usd

EBITDA TTM

151.23M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

735.31M usd

Net debt

N/A usd

About

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.